Immunostimulants drugs - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.98 [0.70, 1.37]< 116%6 studies (6/-)55.4 %some concernserious moderatecrucial-
deaths (time to event analysis only) 0.93 [0.47, 1.85]< 10%1 study (1/-)58.2 %lownot evaluable highcrucial-
clinical improvement 0.99 [0.73, 1.33]> 15%3 studies (3/-)46.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.42 [0.65, 3.10]> 10%1 study (1/-)81.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 3.41 [1.33, 8.73]> 10%1 study (1/-)99.5 %some concernnot evaluable moderateimportant-
clinical worsening 0.27 [0.06, 1.25]< 10%1 study (1/-)95.3 %some concernnot evaluable moderateimportant-
death or ventilation 1.05 [0.90, 1.23]< 10%1 study (1/-)27.2 %some concernnot evaluable moderateimportant-
hospital discharge 3.44 [0.64, 18.49]> 10%1 study (1/-)92.4 %some concernnot evaluable moderateimportant-
ventilation 0.29 [0.05, 1.56]< 10%1 study (1/-)92.5 %some concernnot evaluable moderateimportant-
ICU admission 0.13 [0.01, 1.46]< 176%2 studies (2/-)95.0 %some concernnot evaluable moderatenon important-

-- safety endpoints 00

serious adverse events 0.96 [0.29, 3.17]< 10%1 study (1/-)52.4 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 95,94,90,91 95, 91, 90